Back to Search
Start Over
[Biosimilars in Gastroenterology - how much uncertainly is ethically acceptable?]
- Source :
-
Zeitschrift fur Gastroenterologie [Z Gastroenterol] 2016 Nov; Vol. 54 (11), pp. 1233-1236. Date of Electronic Publication: 2016 Nov 02. - Publication Year :
- 2016
-
Abstract
- Biosimilars use raises uncertainties with regards to efficacy despite potentially significant cost reductions. This requires a classical harm-benefit analysis. Important stakeholders include physicians and patients, companies producing biologica (drugs containing biotechnology-derived proteins as active substance), and companies producing biosimilars, as well as health insurance companies and politicians. They all have their distinct interests. In a rule-setting process, transparency is needed to protect the trust between patients and physicians. In an ideal world, the price of biologica without patent protection would be negotiated in a way that makes biosimilars unnecessary.<br /> (© Georg Thieme Verlag KG Stuttgart · New York.)
Details
- Language :
- German
- ISSN :
- 1439-7803
- Volume :
- 54
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Zeitschrift fur Gastroenterologie
- Publication Type :
- Academic Journal
- Accession number :
- 27806412
- Full Text :
- https://doi.org/10.1055/s-0042-118192